|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
US20190031785A1
(en)
*
|
2016-01-13 |
2019-01-31 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
BR112018071612A2
(pt)
|
2016-04-22 |
2019-02-19 |
Alligator Bioscience Ab |
polipeptídeos biespecíficos inovadores contra cd137
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
MX2018014950A
(es)
*
|
2016-06-07 |
2019-04-25 |
Macrogenics Inc |
Terapia de combinacion.
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018045110A1
(en)
*
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
HRP20251424T1
(hr)
*
|
2016-08-30 |
2025-12-19 |
Xencor, Inc. |
Bispecifična imunomodulacijska protutijela koja se vežu na kostimulacijske receptore i receptore imunosnih kontrolnih točaka
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
EP3515951B1
(en)
*
|
2016-09-23 |
2024-02-28 |
Merus N.V. |
Binding molecules that modulate a biological activity expressed by a cell
|
|
EP3515494B1
(en)
*
|
2016-09-26 |
2026-02-25 |
The Brigham and Women's Hospital, Inc. |
Regulators of b cell-mediated immunosuppression
|
|
SG10201913263SA
(en)
|
2016-09-29 |
2020-03-30 |
Beijing Hanmi Pharmaceutical Co Ltd |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
WO2018090950A1
(zh)
*
|
2016-11-18 |
2018-05-24 |
北京韩美药品有限公司 |
抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
US11535666B2
(en)
*
|
2016-12-30 |
2022-12-27 |
Cytocares (Shanghai) Inc. |
Trifunctional molecule and application thereof
|
|
CA3047070A1
(en)
*
|
2017-01-03 |
2018-07-12 |
F.Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
CA3053275A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Dragonfly Therapeutics, Inc. |
Proteins binding psma, nkg2d and cd16
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
BR112019017628A2
(pt)
*
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
MX2019010156A
(es)
*
|
2017-02-27 |
2020-01-09 |
Dragonfly Therapeutics Inc |
Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
|
|
CN107043425B
(zh)
*
|
2017-03-27 |
2019-05-10 |
顺昊细胞生物技术(天津)股份有限公司 |
抗pd1和cd20双特异性抗体及其应用
|
|
CN106986939B
(zh)
*
|
2017-03-27 |
2019-06-07 |
顺昊细胞生物技术(天津)股份有限公司 |
抗pd-1和tem-8双特异性抗体及其应用
|
|
CN106939050B
(zh)
*
|
2017-03-27 |
2019-05-10 |
顺昊细胞生物技术(天津)股份有限公司 |
抗pd1和cd19双特异性抗体及其应用
|
|
EP4328241A3
(en)
*
|
2017-04-28 |
2024-06-05 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
AU2018271872A1
(en)
*
|
2017-05-23 |
2019-12-12 |
Dragonfly Therapeutics, Inc. |
A protein binding NKG2D, CD16 and ROR1 or ROR2
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
TW201904588A
(zh)
*
|
2017-06-25 |
2019-02-01 |
美商西雅圖免疫公司 |
引導及導航控制蛋白質之製造及使用方法
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
US11725060B2
(en)
|
2017-07-20 |
2023-08-15 |
Aptevo Reserch and Development LLC |
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
IL311488A
(en)
*
|
2017-08-23 |
2024-05-01 |
Dragonfly Therapeutics Inc |
Proteins that bind D2NKG, 16CD, and tumor-associated antigen
|
|
RU2021110369A
(ru)
*
|
2017-09-07 |
2021-06-01 |
Драгонфлай Терапьютикс, Инк. |
Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたil-2 fc融合タンパク質
|
|
EP3502140A1
(en)
*
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
SG11202004158QA
(en)
*
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
WO2019153200A1
(zh)
*
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
CN112119093A
(zh)
*
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
WO2019166650A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3773621A4
(en)
*
|
2018-03-27 |
2022-03-23 |
Systimmune, Inc. |
GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
EP3774914A2
(en)
*
|
2018-04-13 |
2021-02-17 |
Affimed GmbH |
Nk cell engaging antibody fusion constructs
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
JP2021523140A
(ja)
*
|
2018-05-07 |
2021-09-02 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
SG11202011139YA
(en)
*
|
2018-05-16 |
2020-12-30 |
Dragonfly Therapeutics Inc |
Protein binding nkg2d, cd16 and a fibroblast activation protein
|
|
CN112384534A
(zh)
*
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
WO2019226658A1
(en)
*
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019224385A2
(en)
*
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
|
EA202091977A1
(ru)
*
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EA202091888A1
(ru)
*
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
WO2020061142A1
(en)
*
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
CN111196856A
(zh)
*
|
2018-11-19 |
2020-05-26 |
三生国健药业(上海)股份有限公司 |
抗her2/pd1双特异性抗体
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020205504A1
(en)
*
|
2019-03-29 |
2020-10-08 |
Compass Therapeutics Llc |
Common light chains and methods of use
|
|
CN113811329B
(zh)
*
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
WO2020232303A1
(en)
*
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
BR112021026309A2
(pt)
*
|
2019-06-26 |
2022-06-07 |
Ap Biosciences Inc |
Anticorpos para ativação de células t
|
|
AU2020332310A1
(en)
*
|
2019-08-16 |
2022-03-10 |
The Regents Of The University Of California |
Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy
|
|
CN118580364A
(zh)
*
|
2019-11-06 |
2024-09-03 |
西雅图免疫公司 |
制导和导航控制蛋白及其制备和使用方法
|
|
CN114829408B
(zh)
|
2019-12-20 |
2024-01-26 |
山东博安生物技术股份有限公司 |
用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021139780A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Shanghai Henlius Biotech, Inc. |
Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
|
|
KR102559355B1
(ko)
*
|
2020-01-31 |
2023-07-25 |
주식회사 제넥신 |
항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
|
|
US20230151115A1
(en)
*
|
2020-03-31 |
2023-05-18 |
University Public Corporation Osaka |
Multispecific antibody and method for producing same
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2021222595A2
(en)
*
|
2020-04-30 |
2021-11-04 |
Virtuoso Binco, Inc. |
Multispecific antibodies targeting cd38 and epcam and uses thereof
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4168451A2
(en)
|
2020-06-22 |
2023-04-26 |
NGM Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
|
CN115698072B
(zh)
|
2020-07-01 |
2023-07-04 |
山东博安生物技术股份有限公司 |
抗gpc3抗体,抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
|
|
CN114057882B
(zh)
*
|
2020-07-31 |
2023-01-06 |
山东博安生物技术股份有限公司 |
多价多特异性抗体
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2023539645A
(ja)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Nkp30に結合する抗体分子およびその使用
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022262678A1
(zh)
*
|
2021-06-15 |
2022-12-22 |
盛禾(中国)生物制药有限公司 |
一种多特异性抗原结合蛋白及其应用
|
|
CN117730103A
(zh)
*
|
2021-08-02 |
2024-03-19 |
盛禾(中国)生物制药有限公司 |
一种多特异性抗原结合蛋白及其应用
|
|
US20240327543A1
(en)
*
|
2021-08-02 |
2024-10-03 |
Shenghe (China) Biopharmaceutical Co., Ltd. |
Multispecific antigen-binding protein and use thereof
|
|
US20260022190A1
(en)
*
|
2022-07-08 |
2026-01-22 |
Shenghe (China) Biopharmaceutical Co., Ltd. |
Heterodimeric fusion protein and use thereof
|
|
EP4565610A1
(en)
*
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
IL327762A
(en)
*
|
2023-10-17 |
2026-06-01 |
Biontech Zhuhai Pharmaceuticals R&D Co Ltd |
Bispecific antibody against ccr8 and ctla4
|
|
TW202540200A
(zh)
|
2023-12-01 |
2025-10-16 |
美商基利科學股份有限公司 |
抗fap-light融合蛋白及其用途
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
CN119751635B
(zh)
*
|
2024-12-30 |
2026-06-12 |
华润生物医药有限公司 |
Il-21的突变体及其制备方法和应用
|